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ABSTRACT
The broad adoption of Electronic Health Records (EHR) has led
to vast amounts of data being accumulated on a patient’s history,
diagnosis, prescriptions, and lab tests. Advances in recommender
technologies have the potential to utilize this information to help
doctors personalize the prescribed medications. In this work, we
design a two-stage attention-based personalized medication recom-
mender system called PREMIER which incorporates information
from the EHR to suggest a set of medications. Our system takes into
account the interactions among drugs in order to minimize the ad-
verse effects for the patient. We utilize the various attention weights
in the system to compute the contributions from the information
sources for the recommended medications. Experiment results on
MIMIC-III and a proprietary outpatient dataset show that PREMIER
outperforms state-of-the-art medication recommendation systems
while achieving the best tradeoff between accuracy and drug-drug
interaction. Two case studies are also presented demonstrating that
the justifications provided by PREMIER are appropriate and aligned
to clinical practices.
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1 INTRODUCTION
Technological advances and digitization have led to the increasing
availability of patient information for healthcare data analytics. The
large repositories of Electronic Health Records (EHR) contain com-
prehensive information about patient visits over time, procedures
and lab tests results, disease diagnosis, prescribed medications, etc.
Research on EHR has ranged from disease inference [21], outcome
prediction [11, 19], to readmission and mortality estimation [20, 31].
The White House Precision Medicine Initiative1 has propelled
the move to develop and personalize treatment regimens to im-
prove health outcomes. The traditional “one size fits all" concept is
being superseded by treatments that are tailor-made for each indi-
vidual. One line of research in this direction is the personalization
of medication recommender systems. In the largest publicly avail-
able benchmark dataset MIMIC-III [12], a patient has on average
of 20 medications. Eliminating all the potential drug-to-drug inter-
actions remains a challenge. While a clinician tries to ensure that
the medications prescribed do not have the common drug-to-drug
interactions, having a medication recommender system suggest a
list of medicines given a patient’s diagnosis, test procedures, etc
that minimizes adverse drug reactions will serve as an important
decision support tool to the clinician.
1https://obamawhitehouse.archives.gov/precision-medicine
Besides recommending a list of medications, providing justifica-
tions for these recommendations is crucial to build trust, thereby
increasing clinicians’ acceptance of the system and patients’ adher-
ence to the medications. Hence, an ideal personalized recommender
system should (a) incorporate patient-specific information such as
diagnosis, procedures underwent, etc culminated over time to per-
sonalize the recommendations; (b) incorporate drug interaction
information to minimize adverse drug interaction; and (c) provide
justification for the recommendations rendered.
Existing recommender systems such as LEAP use the records
of patients’ current visit and the drug-to-drug interactions to pre-
dict a list of medications [35, 37]. These systems do not consider
information from patients’ previous visits, leading to lower accu-
racy. Further, no justification is provided for the recommendations.
Other recommender systems such as DMNC [16] capture the tem-
poral dependencies in patients’ past visits when predicting medi-
cations. However, these systems do not consider the interactions
between drugs which may lead to adverse drug events, particu-
larly in patients with co-morbidity [22]. For example, the usage of
anti-inflammatory and anti-rheumatic medications together with
sedatives could result in diabetic retinopathy [32].
The GameNet recommender system [24] employs dynamic mem-
ory in conjunction with recurrent neural networks to model tem-
poral dependency in patients’ EHR. The authors use Graph Convo-
lutional Networks (GCN) to model the interactions between drugs.
However, this approach does not use a weighted combination of
patient’s diagnosis, procedures and past medications when retriev-
ing relevant drug interaction information, and is unable to provide
justification for the recommendations.
In this work, we propose a recommender system for medications
called PREMIER that takes into account the past and current visits
of patient records, drug co-occurrences in the EHR, as well as the
known interactions of drugs, to generate personalized medications
with justifications while minimizing adverse drug reactions. There
are two key stages in PREMIER. The first stage extracts patient-
specific information such as the patient’s diagnosis, procedures and
his/her previously prescribed medications to create a personalized
query vector. The second stage takes as input the query vector
to retrieve potential drug interactions from the drug interaction
repository, as well as drug co-occurrences from the EHR of all
patients, thus ensuring that the predicted set of medications has
minimal drug interactions.
By utilizing a two-level neural attention model instead of the
traditional RNN in the first stage, and a graph attention network
[33] in the second stage, PREMIER is able to identify the top con-
tributors for each medication recommended, thereby giving the
justifications for the recommendations. Experimental results on the
benchmark MIMIC-III EHR and a proprietary outpatient dataset
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demonstrate that PREMIER outperforms state-of-the-art medica-
tion recommender systems in terms of accuracy with lower DDI.
Our contributions can be summarized as follows:
• We propose a two-stage recommender system that combines
attention-based recurrent network modeling patients’ visit
with knowledge graph networkmodeling drug co-occurrences
in the EHR and known drug interactions.
• We determine the percentage of contribution from the vari-
ous information sources, that is, diagnosis, procedures, pre-
viously prescribed medications, to identify the key reasons
for recommending a particular medication.
• We perform extensive quantitative and qualitative analysis
of PREMIER on two datasets. Case studies on two patients
indicate that the justifications provided by PREMIER are
aligned with clinical practices.
2 RELATEDWORK
Research in medication recommender systems can be broadly clas-
sified into rule-based, instance-based and longitudinal.
Rule-based recommendations. This approach typically relies on
a collection of rules that capture the knowledge of a medical expert.
Solt and Tikk [27] propose rules to extract medication informa-
tion from discharge summaries. Chen et al. [4] derive knowledge
patterns from medical information such as disease, symptoms, de-
mographics, measurements, etc of a patient to recommend preferred
treatments for chronic heart failures.
The work in [10] attempts to develop adaptive treatment recom-
mendation for adolescent depression based on hard-coded protocols.
Lakkaraju et al. [15] use Markov Decision Process (MDP) to learn
the mapping between patient characteristics and treatments. In gen-
eral, rule-based systems cannot scale or generalize well. Further, it
is difficult to add rules to an already large knowledge base without
introducing conflicting rules.
Instance-based recommendations. In this approach, only the
current visits of patients are used for medication recommendation.
The work in [37] formulates the medication recommender problem
as a multi-instance multi-label learning task and develops the LEAP
algorithm. A recurrent decoder is used to facilitate sequential deci-
sion making to model drug-disease relation along with DDI from
the EHR records. Once this model is trained on patients’ EHR, it
predicts medications based on the diagnosis of a patient’s current
visit.
Wang et al. [35] jointly embed patient demographics, diagno-
sis, past medications into a lower dimensional space and use this
embedding for recommendation. They formulate the task of drug
recommendation as a link prediction problem taking into consider-
ation a patient’s diagnosis and adverse drug reactions. The work
in [34] also exploits demographics, diagnosis, and medication infor-
mation and fuse them with a trilinear method. All these approaches
ignore patients’ diagnosis, etc. from the past visits leading to loss
in accuracy and hence, do not personalize well.
Longitudinal recommendations. This class of recommender sys-
tems aims to exploit the temporal dependencies among a patient’s
past visits. The work in [30] clusters the medical records of patients’
past visits into cohorts based on their treatment similarities in order
to find patterns in the treatment regimens.
Bajor and Lasko propose to use Recurrent Neural Networks
(RNN) to predict medications from a patient’s clinical history and
billing codes in the EHR [2]. While their model can predict if a
drug is being used by a patient, it is unable to recommend multiple
medications for complex disease conditions. The work in [5] pro-
poses an attention-based predictive model to perform various tasks
such as disease and medication prediction. Le et al. [16] introduce
DMNC which infuses the concept of memory augmented neural
networks [29] with RNNs to help in the handling of long-range de-
pendencies by incorporating two memory modules for medication
recommendation. All these works ignore drug interactions.
Shang et al. propose a system called GameNet [24] which con-
siders patients’ longitudinal visit history and drug interactions.
They use dynamic memory and Graph Convolutional networks
(GCN) to personalize the medication recommendations. However,
GCN assumes that the interactions between different drugs have
the same weights, which is not the case in practice. For example,
the adverse drug event of long-term or permanent paralysis as a
result of using an anti-inflammatory medication like Ibuprofen to-
gether with an anticoagulant medication like Enoxaparin is clearly
more severe compared to having diarrhea after using Ibuprofen
and a constipation medication like Linaclotide. In addition, GCN
remains a black-box although attempts have been made to provide
explanations via feature visualization [36].
3 METHODOLOGY
The EHR of a patient can be represented as a sequence of t visits.
Figure 1 shows a sample EHR of a patient with three visits. The ith
visit is given by
x i = [di ,pi ,mi ]
where di ,pi ,mi are multi-hot vectors capturing the diagnosis, pro-
cedure and medication respectively, i = 1, 2, ..., t . Diagnosis and
procedures are encoded with ICD-9 system [26] while medications
are encoded with ATC classification [1]. The total number of diag-
nosis, procedure and medications are denoted as Nd , Np and Nm
respectively.
530.7, 344.00, 285.1, 
599.0, 577.1, V12.51, 
907.2, 337.9, 442.84
442.84, 578.1, 344.00, 
305.01, 305.60, 599.0, 
305.1, 305.20, V16.3, 
V12.51
Visit 1 Visit 2
Time
Diagnosis
Procedures
A06A, A12A, B05C, N02B, 
A12B, A12C, A02B, 
'N05C', A04A, N05B, 
N02A, N05A, B02B, C05A
Medications
A06A, A07A, A12B, A12A, 
A12C, A02B, N05C, A04A, 
N02A, B03A
442.84, 599.0, 285.1, 
790.7, 9072, E9298, 
V12.51, 411.1, V09.0, 
577.1
A06A, N02B, A12B, 
A02B, B02B, A12C, 
J01M, N02A, N05B, 
D04A, J01E
Visit 3
4513, 9904, 3893 4444, 3893, 9904 4444, 8847, 9904
Figure 1: Sample EHR depicting a sequence of three visits.
We use an adjacency matrix AC to indicate the number of drug
co-occurrences in the EHR, in other words, the number of times
a pair of drugs have been prescribed together to patients over
multiple visits. In addition, we also have an adjacency matrixAD to
indicate whether two drugs are known to have some adverse drug
interaction. We construct this matrix from the DDI database [32].
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Given a patient with past visits [x1,x2, ...,xt−1], the diagnosis
dt and procedure pt codes for the current visit, together with the
drug co-occurrence AC and drug interaction information AD , the
task is to predict and justify a list of personalized medications for
the patient’s current visit xt .
We observe that a clinician typically refers to the diagnosis,
procedures, drug-drug interaction, and prescriptions of a patient’s
past visits (along with diagnosis and procedures of the current visit)
when deciding on the appropriate medications for the current visit.
Further, this information may have different weights depending on
their relevance to the current visit’s diagnosis and procedures. This
motivates us to develop a two-stage recommender system called
PREMIER as shown in Figure 2.
The first stage uses two neural attention models, one for proce-
dures and another for diagnosis. This configuration allows us to
alleviate the problem of missing modalities which are common oc-
currences in EHR. For example, we have patients whose diagnosis
codes are available but the procedure codes are absent because the
procedures are not recorded or no procedure has been ordered for
the patient.
Each neural attention model has two levels to learn the impor-
tance of the various visits, and the importance of the diagnosis (or
procedures) of these visits to the current visit. This allows varying
attention at the visit level as well as at the diagnosis or procedure
level within a visit. In other words, our two-level model gives us the
flexibility of selecting which aspect is to be given more attention
when predicting medications. Further, these attention weights also
provide some degree of explanation as opposed to standard RNNs
which are hard to interpret.
The second stage employs graph attention networks which al-
lows for the flexibility of incorporating the frequency of drug co-
occurrences and the severity of drug interactions to learn an effi-
cient representation that will improve the accuracy of the predicted
medications while reducing adverse drug interactions as well as
providing justification for the recommendations.
We describe the details of PREMIER in the following subsections.
Table 1 summarizes the notations used.
3.1 Create Query Vector
Given a patient with t visits, we linearly embed the diagnosis,
procedure and past medication vectors into a 64-dimensional space
to learn the distributed representations, denoted as dei , pei ,m
e
i , for
1 ≤ i ≤ t by using the embedding matrices Ed , Ep , Em respectively.
The embeddings of the diagnosis and procedure vectors are passed
to the respective neural attention models as shown in Figure 2.
Consider a neural attention model similar to [5] that takes as
input the diagnosis embedding. We model the visit-level attention
as αd where the ith entry, αd [i], is a scalar value depicting the
weight for the ith visit, 1 ≤ i ≤ t . Separately, we also model
the diagnostic-level attention of a visit as βd where the jth entry,
βd [j], is a vector depicting the weights of the various diagnostic
code embeddings, 1 ≤ j ≤ t .
We utilize RNNdα to compute the attention vector αd as follows:
д1,д2, ...,дt = RNN
d
α (de1 ,de2 , ...,det )
αd = so f tmax(ϕ(д1),ϕ(д2), ...,ϕ(дt ))
(1)
Table 1: Notations used in PREMIER
Notation Description
Nd Total number of diagnosis
Np Total number of procedures
Nm Total number of medications
di ∈ RNd Multi-hot vector of diagnosis codes
pi ∈ RNp Multi-hot vector of procedure codes
mi ∈ RNm Multi-hot vector of medication codes
AC ∈ RNm×Nm Adjacency matrix of drug co-occurrence
AD ∈ RNm×Nm Adjacency matrix of drug interaction
ZC ∈ R64×Nm Drug co-occurrence representation
ZD ∈ R64×Nm Drug interaction representation
α ∈ Rt Visit level attention
β ∈ R64×t Variable level attention
γ t ∈ Rt−1 Past medication attention
λt ∈ RNm Graph network attention
rdt ∈ R64 Response vector for diagnosis
r
p
t ∈ R64 Response vector for procedures
ct ∈ R64 Context vector
vt ∈ R64 Visit history vector
qt ∈ R64 Query vector
ot ∈ R64 Output vector
yˆt ∈ RNm Medication recommendation
where each дi is a hidden layer in RNNdα and ϕ is a linear transfor-
mation function in which the weight vector ∈ R64×1.
Similarly, we use a second RNNd
β
to obtain βd [j]:
h1,h2, ...,ht = RNNdβ (d
e
1 ,d
e
2 , ...,d
e
t )
βd [j] = tanh(ψ (hj )), j = 1, 2, ..., t
(2)
where each hj is a hidden layer in RNNdβ and ψ is a linear trans-
formation function in which the weight matrix ∈ R64×64.
With the generated attentions, we determine the response vector
rdt of diagnosis as follows:
rdt =
t∑
i=1
αd [i]βd [i] ⊙ dei (3)
where ⊙ denotes element-wise multiplication and r i ∈ R64×1.
The response vector for procedure, rpt , can be obtained similarly.
With this, we can define a context vector ct as follows:
ct = r
d
t +w1r
p
t (4)
where rdt and r
p
t are the response vectors for diagnosis and proce-
dure respectively, andw1 is a parameter to learn.
We insertct into a repository of the context vectors for a patient’s
past visits as well as the corresponding embedded medications
which are stored in the form of key-value pairs where the key is
the context vector and the value is the embedded medications. In
other words, the repository consists of a stack of tuples <ci ,mei >,
i ∈ [1, t − 1].
Given the context vector ct for the current visit t , we compute
the attention on the context vectors of the previous visits as follows:
γ t = so f tmax(c1 · ct , c2 · ct , ...,ct−1 · ct ) (5)
3
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Figure 2: Details of PREMIER.
With this attention,γ t ∈ Rt−1, we obtain the visit history vector
vt where the ith entry is given by
vt [i] = γt [i] ·mei (6)
Finally, we combine the context vector and the visit history
vector to form the query vector qt ∈ R64 as follows:
qt = ct +w2vt , w2 ∈ R. (7)
3.2 Retrieve Drug Information
Having created the query vector, we will use it to retrieve the drug
co-occurrence and drug interaction information. Recall that we
have captured the co-occurrences of drugs in EHR in the form of an
adjacency matrix AC , and the known drug interaction information
in another adjacency matrix AD .
We use two graph attention networks, one for drug co-occurrences
and another for drug interactions, to learn an efficient represen-
tation for recommendation (see Figure 2). This allows PREMIER
to model the severity of drug interactions. Each graph attention
network has two layers. The first layer utilizes two attention heads,
while the second layer has one attention head.
We first consider the drug co-occurrence graph attention net-
work. The input to a node nj in the first layer of this network is the
jth row in the feature matrix. Since in this context, the nodes do
not have features, an identity matrix I is used as the feature matrix
depicting the presence of the node itself. Let Nj be the set of drugs
that co-occur with j which is found by considering the positions in
the jth row of AC having a non-zero value. Then the output ne1j is
given by:
ne1j = ∥2b=1σ
©­«
∑
k ∈Nj
δbjkW
bnk
ª®¬ (8)
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where ∥ denotes concatenation,W b ∈ R64×Nm is the embedding
matrix for the bth attention head, and δbjk is the attention weight
between the pair of drugs j and k computed as follows:
δbjk =
exp(LeakyReLU(aT [W bnj ∥W bnk ]))∑
f ∈Nj exp(LeakyReLU(aT [W bnj ∥W bnf ]))
(9)
where aT is the transpose of the weight vector of a single layer
feed-forward neural network.
The final representation of a drug j is obtained from the second
layer of the graph attention network as follows:
ne2j = σ
©­«
∑
k ∈Nj
δjkWn
e1
k
ª®¬ (10)
whereW ∈ R64×128 is the embedding matrix.
With this, we can generate the drug co-occurrence represen-
tation ZC ∈ R64×Nm . In the same manner, the drug interaction
graph attention network is used to obtain the drug interaction
representation ZD ∈ R64×Nm .
We can compute the attention λt based on these representations
and the query vector qt as follows:
λt = so f tmax((ZC +w3ZD )T · qt ) (11)
where (ZC +w3ZD )T is the transpose of (ZC +w3ZD ) andw3 is a
parameter to learn.
The final output vector ot is obtained as:
ot = qt +w4((ZC +w3ZD ) · λt ), w4 ∈ R (12)
We obtain a vector yˆt by passing ot through a linear transforma-
tion followed by a sigmoid function. A medication k is considered
predicted if yˆt [k] > 0.5, k ∈ {1,Nm }. Using Equations (4) and (7),
we have
yˆt = F
(
rdt +w1r
p
t +w2vt +w4((ZC +w3ZD ) · λt )
)
(13)
3.3 Justify Recommended Medications
In this section, we describe how we justify the recommended med-
ications by determining the percentage of contribution from di-
agnosis, procedures and previously prescribed medications, and
highlighting the top contributors.
Let us consider the jth medication recommended at the current
t th visit. Combining the first term in Equation (13) with Equa-
tion (3), we obtain the contribution due to a patient’s diagnosis:
score_diaдnosis = ∥ti=1
(
αd [i]EF [j, :]
(
βd [i] ⊙ Ed [:,k]
)
di [k]
)
where di [k] denotes a specific diagnosis in the ith visit where
k ∈ {1,Nd }, Ed denotes the embedding matrix for di and EF is the
weight matrix used in the linear transformation function F .
Similarly, we can compute the contribution due to the procedures
undergone by the patient, from the second term in Equation (13)
and Equation (3) as follows:
score_procedure = ∥ti=1w1αp [i]EF [j, :]
(
βp [i] ⊙ Ep [:,k]) pi [k]
where pi [k] denotes a specific procedure in the ith visit where
k ∈ {1,Np } and Ep denotes the embedding matrix for pi .
In order to determine the contribution due to the past prescribed
medications, we substitute Equation (6) to the third term in Equa-
tion (13) as follows:
score_medication = ∥t−1i=1w2γt [i]
(
EF [j, :] · Em [:,k]
)
mi [k]
wheremi [k] denotes the specific medication prescribed in the ith
visit where k ∈ {1,Nm } and Em denotes the embedding matrix for
mi .
We calculate the contributions due to drug co-occurrences and
drug interactions as follows:
score_occurrence = w4EF [j, :]ZC · λt
score_interaction = w4w3EF [j, :]ZD · λt
where ZC and ZD are obtained from graph attention networks as
described in Section 3.2.
The final contributions are obtained by normalizing the five
scores such that they add up to 1. We rank these scores and use the
top-2 scores as justification for the recommendations.
3.4 Loss Functions
There are three loss functions in PREMIER, namely, binary cross
entropy loss, multi-label hinge loss, and drug-drug interaction loss.
The binary entropy loss Lentropy is defined as:
Lentropy = −
t∑
i=1
Nm∑
k=1
(yi [k] log yˆi [k] + (1 − yi [k]) log(1 − yˆi [k]))
(14)
where Nm is the total number of medications, yˆi [k] and yi [k] are
the kth predicted and ground truth medication for the ith visit.
LetU be the set of positions where the entry in the ground truth
medication vector yt is 1. We define the multi-label hinge loss to
ensure that the score of the correctly predicted class is higher than
the scores of the other predicted class as follows:
Lhinge =
t∑
i=1
Nm∑
k=1
∑
u ∈U
max(0, 1 − (yˆi [u] − yˆi [k]))
|U | (15)
where yˆi [k] denotes the kth coordinate of the prediction vector at
the ith visit.
The drug-to-drug interaction loss, denoted as Ladverse, penalizes
the pairs of drugs that have adverse interactions and is defined as:
Ladverse =
t∑
i=1
Nm∑
j=1
j−1∑
k=1
(AD ⊙ yˆ⊺i yˆi )[j,k] (16)
The combined loss is then a weighted sum of the three losses:
Lcombine = γ1Lentropy + γ2Lhinge + γ3Ladverse (17)
where γ1 + γ2 + γ3 = 1.
4 PERFORMANCE STUDY
In this section, we present the results of the experiments we carry
out to evaluate the performance of PREMIER for medication recom-
mendations. We use the largest publicly available MIMIC-III [12]
EHR dataset which contains clinical data for 7870 neonates (infants)
and 38,597 adults admitted to ICU between 2001 and 2008, and cap-
tures attributes such as lab reports, vital signs, medications, etc.5
This dataset uses the ICD-9 coding system for diagnosis, and the
NDC (National Drug Code) system for medications.
We pre-process the dataset to filter out those patients that have
only one visit. We create the drug interaction adjacency matrix
AD from the TWOSIDES dataset [32] using the top-40 interactions
for each drug because these cover the major severe effects, similar
to [24]. Since the TWOSIDES dataset uses the ATC Third Level
drug classification system, we transform the NDC coding of the
medications in MIMIC III to ATC coding and create the drug co-
occurrence adjacency matrix AC . Table 2 gives the characteristics
of the dataset obtained.
Table 2: Dataset Characteristics
Attribute Statistics
Number of patients 6350
Number of diagnosis 1958
Number of procedures 1430
Number of medications 151
Average number of visits per patient 2.36
Average number of diagnosis per visit 13.63
Average number of procedures per visit 4.53
Average number of medications per visit 19.85
Maximum number of diagnosis per visit 39
Maximum number of procedures per visit 32
Maximum number of medications per visit 55
We divide the dataset into training, validation and test sets in
the ratio of 4:1:1. The hyperparameter values are adjusted on the
validation set which resulted in the mixture weights γ1 = 0.79,γ2 =
0.01 and γ3 = 0.2. The embedding size for our model is fixed at 64
and training is done using Adam [14] with a learning rate of 0.0001.
The size of the hidden layers for the neural attention models is set
to 64. Gated recurrent units (GRU) are used for RNN blocks, since it
is efficient and widely used for modeling sequential dependencies.
In order to avoid overfitting, we apply a dropout [28] on the input
embedding layer with a value of 0.4. The best performing model
is chosen based on the performance on the validation set after 40
epochs. The implementation is done in PyTorch and the models are
trained on two NVIDIA Titan RTX GPU. The results reported are
on the test set.
4.1 Evaluation Metrics
We evaluate the accuracy of the predictions with the commonly
used metrics AUC [24], F1 [24] and Jaccard similarity coefficient
[37]. We also use the DDI metric proposed in [24] to measure the
percentage of pairwise drug interactions in the list of predicted
medications. A low value for DDI is desirable since it indicates
fewer drug interactions.
Since our objective is to maximize the number of correctly pre-
dicted medications and minimize the drug interactions, we intro-
duce a metric called DScore that captures the tradeoff between
accuracy and adverse reactions:
DScore = 2 × ACC × (1 - DDI)ACC + (1 - DDI) (18)
where ACC denotes an accuracy measure.
Depending onwhether we use AUC, F1 or Jaccard as the accuracy
measure, we have three variants of DScore, denoted as DScoreAUC,
DScoreF1, DScoreJac respectively. A high DScore indicates that
the set of predicted medications is close to the set of prescribed
medications with a low drug-to-drug interaction rate.
4.2 Comparative Experiments
We compare PREMIER with several baseline approaches as well as
state-of-art medication recommender systems:
• Logistic Regression [18]. Here, we use the binary relevance
implementation of logistic regression with L2 regularization
since our recommendation is multi-label in nature.
• LEAP [37]. This is a sequential decision making system
which provides recommendations based on the current visit.
• DMNC [16]. This is a dual memory neural computer that
prescribes a set of medications based on the information of
the past visits stored in the external memory components.
• GameNet [24]. This work models the patient data as a col-
lection of his past visits together with drug interaction in-
formation.
Table 3 shows the results of this experiment. We see that PRE-
MIER achieves the best performance in terms of accuracy and
DScores as it takes into account the past prescribed medications
and the varying importance of drug interactions. In terms of DDI,
although LEAP has the best performance, its accuracy is the worst.
This is reflected in LEAP having the lowest DScores.
Note that PREMIER does not completely remove the DDI in its
list of recommended medications. This is unavoidable as there al-
ready exists some degree of DDI in the underlying EHR dataset
which is used for training and testing the model. In other words,
the medications prescribed by clinicians also contain some drug
interactions. In fact, the DDI in the actual prescribed medications in
the test set is 0.0750 which is similar to that attained by PREMIER.
Further, the average number of actual medications prescribed per
visit in the test set is 20.60 which is close to the average number of
medications recommended by PREMIER.
Effect ofNumber of Visits.We examine the impact of the number
of visits on the performance of various methods. For this analysis,
we use the cohort of patients with exactly 5 visits since there are
very few patients with more than 5 visits. We exclude LEAP and lo-
gistic regression from this analysis as they do not use patients’ visit
information. Figure 3 shows the results. We observe that PREMIER
outperforms GameNet and DMNC in terms of AUC and DDI, indi-
cating that PREMIER can effectively utilize patients’ visit history
and strive to recommend safe medications without compromising
on the accuracy aspect.
We also compare the performance of the recommender systems
for patients with fewer than 3 visits. Table 4 shows the results on
this cohort of patients. We see that PREMIER continues to be the
best performer with almost the same accuracy and DDI, while the
other methods have a larger decrease in accuracy and increase in
DDI. This indicates that PREMIER remains effective and is robust
even for patients with few visits.
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Table 3: Results of Comparative Study in MIMIC-III.
Methods Accuracy
Drug
Interaction Tradeoff Average #MedicationsAUC F1 Jaccard DDI DScoreAUC DScoreF1 DScoreJac
Logistic Regression 0.6549 0.6144 0.4545 0.0792 0.7654 0.7370 0.6085 14.21
LEAP 0.6418 0.6064 0.4435 0.0665 0.7606 0.7352 0.6013 19.01
DMNC 0.6637 0.6188 0.4450 0.0899 0.7676 0.7366 0.5977 23.60
GameNet 0.7472 0.6561 0.4998 0.0790 0.8250 0.7663 0.6479 25.06
PREMIER 0.7795 0.6812 0.5269 0.0750 0.8460 0.7845 0.6713 22.65
Table 4: Results of Comparative Study in MIMIC-III for patients with few visits (< 3).
Methods Accuracy
Drug
Interaction Tradeoff Average #MedicationsAUC F1 Jaccard DDI DScoreAUC DScoreF1 DScoreJac
Logistic Regression 0.6275 0.5933 0.4422 0.0822 0.7453 0.7207 0.5968 14.32
LEAP 0.6329 0.5955 0.4300 0.0664 0.7543 0.7271 0.5888 19.86
DMNC 0.6453 0.6002 0.4343 0.0931 0.7540 0.7223 0.5873 21.37
GameNet 0.7303 0.6466 0.4853 0.0799 0.8142 0.7594 0.6354 25.27
PREMIER 0.7788 0.6803 0.5264 0.0746 0.8457 0.7841 0.6710 22.73
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Figure 3: Effect of number of visits.
Number of Recommended Medications. Table 5 shows the av-
erage number of extra medications recommended as well as the
average number of medications that are missed by the various ap-
proaches per visit. We observe that LEAP misses the most number
of medications, suggesting that considering information from pre-
vious visits is important. When we examine the extra medications
recommended, we find the GameNet has the highest number of
extra medications, indicating that not capturing the severity level
of drug interaction may lead to over recommendation.
In contrast, PREMIER has the least number of missed medica-
tions per visit. The number of extra medications recommended by
PREMIER is also relatively low. This suggests that having different
attention weights for various instances in multiple information
sources while allowing the model to learn the varying severity of
drug interactions helps to boost the performance.
Table 5: Average number of missed and extra medications.
Methods # Missed # Extra
Logistic Regression 9.50 3.11
LEAP 8.00 7.29
DMNC 6.96 9.22
GameNet 5.71 10.58
PREMIER 5.49 7.55
4.3 Ablation Study
In this section, we carry out an ablation study to better under-
stand the impact of the various components in PREMIER on its
performance. We have the following variants:
(1) PREMIER[diagnosis, procedure]. This variant uses only the
diagnosis and procedure codes of all the visits to predict the
list of medications.
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Table 6: Results of Ablation Study
Methods Accuracy
Drug
Interaction Tradeoff
AUC FI Jaccard DDI DScoreAUC DScoreF1 DScoreJac
PREMIER [diagnosis, procedure] 0.7456 0.6643 0.5086 0.0810 0.8232 0.7711 0.6548
PREMIER [diagnosis, procedure, drug repository] 0.7473 0.6650 0.5094 0.0781 0.8254 0.7726 0.6562
PREMIER [diagnosis, procedure, medication] 0.7508 0.6701 0.5103 0.0790 0.8272 0.7757 0.6567
PREMIER 0.7795 0.6812 0.5269 0.0750 0.8460 0.7845 0.6713
(2) PREMIER[diagnosis, procedure, drug repository]. Thismodel
uses only the diagnosis and procedure codes along drug in-
formation in the repository. It does not use the medications
from the past visits of patients. In other words, patients’
previously prescribed medication information is not incor-
porated in this model.
(3) PREMIER[diagnosis, procedure, medication]. This model
does not have the drug interaction information. In other
words, it uses the diagnosis and procedure codes as well as
the medication prescribed in the past visits of patients.
Table 6 presents the results for the different variants of PREMIER.
As expected, using only diagnosis and procedure information has
the lowest accuracy and DScores with the highest DDI. Incorpo-
rating drug co-occurrence and drug interaction information helps
to reduce the DDI. We observe improvements in all the accuracy
measures and DScore when we take into account past medications.
Compared to PREMIER[diagnosis, procedure], we see that the
DDI is lower for other variants because the past medication infor-
mation implicitly contains some knowledge of drug co-occurrences
and drug interactions. A sharp improvement for both accuracy mea-
sures and DDI is achieved when we consider all the information.
4.4 Case Study
We present two use cases to demonstrate how PREMIER provides
justification for the recommended medications.
Figure 4: Distribution of justifications for medications.
Patient A. This patient has been diagnosed with malignant neo-
plasm of liver and drug-induced delirium, and subsequently went
on to have a liver transplant surgery. The patient returned for a sec-
ond visit and was diagnosed with septic shock with severe sepsis, a
potentially life-threatening condition caused by the body’s response
to an infection caused by bacteria2. We analyze the medications
recommended to Patient A.
Figure 4(a) shows the distribution of the justifications for the
medications recommended to Patient A. We observe that diagnosis
contributes nearly 50% to the list of medications recommended, pro-
cedures contribute close to 40% while past medications contribute
to the remaining 12%.
Table 7 gives a sample of the prescribed medications, recom-
mended medications and the corresponding justifications, color-
coded as shown in Figure 4, which are based on the top-2 con-
tribution scores obtained from PREMIER. We see that the justifi-
cations for the medications in Rows 1 to 3 are primarily due to
the diagnosis sepsis. The first two medications Ciprofloxacin and
Piperacillin belong to the class intestinal anti-infectives and beta-
lactam anti-bacterials respectively. The justifications make sense
as these medications are known to treat sepsis [6].
Further, the second highest contributor in Row 2 is the procedure
liver transplant which Patient A has undergone previously. This
makes sense as liver transplant is known to increase the risk of
sepsis. The third medication is Zinc Sulfate, a mineral supplement
that is often prescribed to prevent infections or re-occurrence of
sepsis [8].
Row 4 shows that Calcium is recommended with the justification
septic shock, another diagnosis for Patient A. This is reasonable
as calcium is typically administered for resuscitation after septic
shock [3].
The medication Acetaminophen in Row 5 is an analgesic and
antipyretic, and the justification shows it is mainly due to the diag-
nosis delirium. Delirium is a serious disturbance in mental abilities
that results in confused thinking and reduced awareness of the
environment 3. Since delirium often stems from pain and fever,
analgesics and antipyretics are administered to reduce the pain and
body temperature to reduce the severity of delirium [7]. We see that
the justifications for the medications recommended are appropriate
and aligned with clinical practices.
Patient B.This patient has been diagnosedwith coronary atheroscle-
rosis and has undergone a surgery involving the bypass of three
coronary arteries. The patient is subsequently diagnosed with se-
vere tracheal disorder and is admitted for a procedure of invasive
mechanical ventilation. Figure 4(b) shows that procedure is the
main contributor to the medications recommended.
2https://www.mayoclinic.org/diseases-conditions/sepsis/symptoms-causes/syc-
20351214
3https://www.mayoclinic.org/diseases-conditions/delirium/symptoms-causes/syc-
20371386
8
Table 7: Sample medications recommended to Patient A and their justifications.
Prescribed Medications Recommended Medications Justification
1 Ciprofloxacin Intestinal Anti-infectives Sepsis (90.36), Septic shock (4.60)
2 Piperacillin and tazobactam Beta-Lactam Anti-bacterials Sepsis (39.64), Liver transplant (20.97)
3 Zinc Sulfate Mineral Supplements Sepsis (31.48), Lacrimal gland operated (26.19)
4 Calcium Gluconate Calcium Septic shock (30.63), Omeprazole (20.56)
5 Acetaminophen Analgesics and anti-pyretics Delirium (48.52), Opioids (15.36)
Table 8: Sample medications recommended to Patient B and their justifications.
Prescribed Medications Recommended Medications Justification
1 Captopril Vasodilators Bypass of coronary arteries (71.34), Atrial fibrillation (19.77)
2 Acebutolol Beta blocking agents Bypass of coronary arteries (89.67), Anemia (2.46)
3 Cisatracurium Besylate Peripherally acting muscle relaxants Mechanical ventilation (90.05), Tracheomalacia (7.55)
4 Diazepam Hypnotics and sedatives Mechanical ventilation (77.09), Bypass of coronary arteries (20.00)
5 Magnesium Sulfate Mineral supplements Mechanical ventilation (57.20), Anemia (30.65)
Table 9: Results on the proprietary test set with an inherent DDI of 0.196, and average number of medications per visit is 4.83.
Methods Accuracy
Drug
Interaction Tradeoff Average #MedicationsAUC F1 Jaccard DDI DScoreAUC DScoreF1 DScoreJac
Logistic Regression 0.5645 0.4455 0.3291 0.3462 0.6058 0.5299 0.4378 1.87
LEAP 0.5879 0.5176 0.3897 0.2600 0.6552 0.6091 0.5105 2.89
GameNet 0.6930 0.6092 0.4850 0.3017 0.6956 0.6507 0.5724 7.28
PREMIER 0.7189 0.6408 0.5398 0.2719 0.7234 0.6816 0.6199 4.27
Table 8 shows the prescribed medications, recommended medica-
tions and their corresponding justifications which is mainly related
to the procedure of coronary bypass surgery. Row 1 is a vasodilator
to dilate blood vessels and is used to facilitate the flow of blood to
reduce the pressure on heart after surgery involving coronaries [13].
Further, the second highest contributor, atrial fibrillation in Row
1 also makes sense as it leads to heart strokes which eventually
requires bypass surgery. Row 2 is a beta-blocking agent to help
lower blood pressure, thus preventing complications after a bypass
surgery.
We observe that, a muscle relaxant (Row 3), is recommended by
PREMIER and the justification given is the procedure mechanical
ventilation. This aligns with the fact that muscle relaxants help
facilitate the intubation or ventilation procedure [25].
The medication in Row 4 is Diazepam which belongs to the
class hypnotics and sedatives and is used to stabilize patients under
ventilation [9]. Since this patient is under invasive mechanical
ventilation, mineral supplements (Row 5) are also recommended to
replenish the physiological stability.
The above two cases studies indicate that that PREMIER is able
to provide sensible justifications.
4.5 Experiments on a Proprietary Dataset
Finally, we apply PREMIER on a one year outpatient dataset. Com-
pared to the inpatient MIMIC III, this proprietary dataset has a
larger patient cohort, but the number of diagnosis per patient is
much fewer. Table 10 gives the characteristics of this dataset.
Table 10: Characteristics of the Proprietary Dataset.
Attribute Statistics
Number of patients 13640
Number of diagnosis 11
Number of medications 134
Average number of visits per patient 3.42
Average number of diagnosis per visit 2.37
Average number of medications per visit 5.04
Maximum number of diagnosis per visit 7
Maximum number of medications per visit 8
We divide the dataset into training, validation and testing in
the ratio 4:1:1. The hyperparameter values are adjusted on the
validation set which resulted in the mixture weights γ1 = 0.75,γ2 =
0.05 and γ3 = 0.2. The embedding size for our model is fixed at 64
with a learning rate of 0.0002 and a dropout value of 0.6. As before,
the size of the hidden layers for the neural attention models is set to
64. The best performing model is chosen based on the performance
on the validation set after 30 epochs, and the reported results are
for the test set.
Since this dataset does not have procedure codes, we adapt PRE-
MIER and GameNet to run without procedure codes. We omit
DMNC as it cannot run without procedure codes. Table 9 gives
the results. We see that PREMIER remains the top performer in
terms of accuracy and DScore. Logistic regression gives the worst
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results followed by LEAP. However, the DDI for LEAP is the lowest
and is closely followed by PREMIER.
In terms of the average number of medications recommended,
we observe that LEAP and logistic regression tend to recommend
significantly fewer medications to patients while GameNet often
over-recommends. On the contrary, the number of medications
recommended by PREMIER is close to that in the ground-truth. This
gives us the confidence that PREMIER is robust and can give good
recommendations on datasets with different kinds of distributions.
5 CONCLUSION AND FUTUREWORK
In this work, we have described an end-to-end system called PRE-
MIER that takes into consideration information from past and cur-
rent visits along with drug information to make accurate recom-
mendations that minimizes adverse drug interactions. The system
works in two stages and jointly models the sequential dependencies
in past visits and drug co-occurrence and interaction information
to derive the recommendations and their justifications. Experiment
results on both a public and private EHR datasets demonstrate the
ability of PREMIER to outperform existing solutions in attaining
the best tradeoff. Case studies also show that the justifications are
appropriate and help patients and clinicians understand why the
medications are recommended.
Future work includes incorporating lab reports [23] and medical
notes [17] which are also a rich source of information and leverage
it to gain additional insights such as patient allergies.
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